CA Patent

CA2493878C — Parenteral formulations containing a rapamycin hydroxyester

Assigned to Wyeth LLC · Expires 2013-07-23 · 13y expired

What this patent protects

This invention provides cosolvent concentrates containing rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), a parenterally acceptable solvent, and an antioxidant. Also provided are parenteral formulations which contain aforementioned concentrat…

USPTO Abstract

This invention provides cosolvent concentrates containing rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), a parenterally acceptable solvent, and an antioxidant. Also provided are parenteral formulations which contain aforementioned concentrate, diluent solvent, and a surfactant and methods for preparing the same.

Drugs covered by this patent

Patent Metadata

Patent number
CA2493878C
Jurisdiction
CA
Classification
—
Expires
2013-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.